Personal Genome Diagnostics
Personal Genome Diagnostics is recorded as a service provider in 7 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 7 of 7 trials · Latest update first
A First-In-Human (FIH) phase I/II open-label, multicentre, dose escalation and expansion trial of VERT-002 in patients with locally advanced or metastatic solid tumors including non-small cell lung cancer (NSCLC) harboring MET alterations.
Sponsor Pierre Fabre Medicament
- Start (EU)
- Latest update
- Estimated end
An Open-Label Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors
Sponsor Eisai Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab versus Placebo, in Combination with Pembrolizumab, Pemetrexed, and Carboplatin, in First-Line Treatment of Participants with Metastatic Non-Squamous Non-Small Cell Lung Cancer (GDFATHER-NSCLC-01)
Sponsor CatalYm GmbH
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients with Solid Tumors Dependent on KIT or PDGFRA Signaling
Sponsor Blueprint Medicines Corp.
- Start (EU)
- Latest update
- Estimated end
A Single-Arm, Open-Label Pharmacokinetic, Safety, and Efficacy Study of ASTX727 in Combination with Venetoclax in Adult Patients with Acute Myeloid Leukemia
Sponsor Taiho Oncology Inc.
- Start (EU)
- Latest update
- Estimated end
I4C-MC-JTBB: A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First-Line Treatment in Metastatic NSLC Patients with Activating EGFR Mutations Who Have Disease Control after an 8-Week Lead-In Treatment with Erlotinib
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
An open-label, multicenter, phase 1b/2 study of E7386 in combination with pembrolizumab in previously treated subjects with selected solid tumors
Sponsor Eisai Limited
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Personal Genome Diagnostics?
The 2026-10-09 snapshot links Personal Genome Diagnostics to 7 distinct CTIS trials. Recorded services include Laboratory services, Analytical Chemistry, ctDNA Sequencing, Molecular profiling. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Personal Genome Diagnostics?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Gastroenterology, Gynecology, Hepatology. Recorded phases include Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Personal Genome Diagnostics conducted?
The linked trials record locations in 11 countries, including Spain, Germany, Italy, France, Austria. These are trial locations, not confirmed office locations or countries where Personal Genome Diagnostics delivered services.
What can this page tell me about Personal Genome Diagnostics's trial experience?
Browse 7 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Personal Genome Diagnostics. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Personal Genome Diagnostics Inc.